1. Ventilated2. With acute and chronic kidney disease3. Previous thromboembolic events4. History of previous anaphylaxis5. Previous history of adverse reaction to intravenous gamma globulin6. Pregnant or lactating woman7. Severe comorbidity: terminal cancer and severe heart disease.8. Body Mass Index (BMI) = 309. With a diagnosis of selective IgA immunodeficiency10. With autoimmune diseases11. That they are using treatment with the anti-CD 6 monoclonal antibody Itolizumab12. History of having received treatment with blood products one month before inclusion in the study.

1. Ventilated2. With acute and chronic kidney disease3. Previous thromboembolic events4. History of previous anaphylaxis5. Previous history of adverse reaction to intravenous gamma globulin6. Pregnant or lactating woman7. Severe comorbidity: terminal cancer and severe heart disease.8. Body Mass Index (BMI) = 309. With a diagnosis of selective IgA immunodeficiency10. With autoimmune diseases11. That they are using treatment with the anti-CD 6 monoclonal antibody Itolizumab12. History of having received treatment with blood products one month before inclusion in the study.